Sol-Gel Technologies
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Sol-Gel Technologies
Sol-Gel Technologies Ltd. 是一家臨床階段的專業製藥公司，專注於開發和商業化基於其在以色列的專有微膠囊遞送系統的外用皮膚病藥物產品。該公司的主要候選產品包括 Twyneo，一種新穎的、每日一次的非抗生素外用乳膏，已完成治療尋常痤瘡的 III 期臨床試驗； Epsolay，一種每日一次的外用乳膏，已完成治療丘疹膿皰性酒渣鼻的 III 期臨床試驗； SGT-210，處於治療掌蹠角化病的I期臨床試驗階段； Erlotinib、Tapinarof 和 roflumilast 用於治療牛皮癬和其他疾病。它還參與了通用局部皮膚病藥物產品的開發。該公司與 Perrigo 有合作。 Sol-Gel Technologies Ltd. 成立於 1997 年，總部位於以色列 Ness Ziona。
如何購買 Sol-Gel Technologies (SLGL)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 SLGL
透過 RockFlow App 或網頁端搜尋 SLGL，輸入您想要投資的金額，然後點擊確認即可完成交易。
Similar Stocks
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.